In this "phosphoroimmunoassay," a phosphorescent label is These two compounds cross reacted equally with the antiserum used; hence, we measured the activity of both in patients' sera. Alternatively, simple pre-treatment of the sample with acid destroys CBZE immunoreactivity and enables specific assay of CBZ. AddItIonal 
pulse and the start of measurement; the "gate time" is the interval during which the signal is subsequently collected after each light pulse.
We used the instrument with "response" setting number 2, and we made measurements with use of the "integration mode" facility, the overall measurement time being 4.2 a. We used a red-sensitive photomultiplier (Perkin-Elmer accessory) throughout this work to ensure adequate response at the high wavelength characteristic of erythrosin phosphorescence.
Preparation Procedures E ythrosin-labeled carbamazepine (CBZ-ETC):
We reacted 3 mg of CBZ-N--ethylainine and 15 mg of E1TC overnight in the dark and at room temperature, in 800 Figure  2 ). Therefore, we designed the assay to measure the combined concentrations of CBZ and CBZE. Alternatively, if only information on CBZ is required, the simple pre-treatment with acid described (see Specific CBZ assay) destroys the immunoreactivity of the epoxide 
Results

Optimization of Assay Conditions
Interferences:
We assessed the possible effects on the PhIA of factors known to interfere in fluoroimmunoassay. Figure  3, left) . When the same specimens were assayed by PhIA after acid pre-treatment, the regression line relating the PhIA (y) and chromatographic (x) results for CBZ only was y = x + 0.3 mg/L, r = 0.99 (Figure  3, right) .
Discussion
We 
